Most peptide users assume the concern is liver toxicity or injection site reactions
10.1038/nature11552 392
PMCID: PMC6678539 Bicknell LS, Farrington-Rock C, Shafeghati Y, Rump P, Alanay Y, Alembik Y, Al-Madani N, Firth H, Karimi-Nejad MH, Kim CA, Leask K, Maisenbacher M, Moran E, Pappas JG, Prontera P, de Ravel T, Fryns JP, Sweeney E, Fryer A, Unger S, Wilson LC, Lachman RS, Rimoin DL, Cohn DH, Krakow D, Robertson SP
When a meal is expanded, GLP-1 gets released and stimulates the secretion of insulin, which inhibits glucagon release and gastric emptying slowly
On tirzepatide, this stimulus is amplified because your stomach is already signaling fullness and delayed emptying